Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SOURCE Nuvalent, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? Details of the poster presentation are as follows: Title:Â Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitor Abstract Number: B057 Authors:Â Yuting Sun*, Kristin L. Andrews, Anupong Tangpeerachaikul, Michael J. Walsh, Nancy E. Kohl, Joshua C. Horan, Henry E. PelishSession: Poster Session B Session Date and Time:Â Friday, October 24, 2025, 12:30-4:00 p.m. ET Location: Exhibit Hall D *Presenter, c ...